Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Clinical trial NCT05124431 · UNKNOWN

Trial details

NCT number: NCT05124431
Sponsor: Fudan University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma

Start date: 2021-12-01
Primary completion: 2023-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.